profit from every $100 of sales.
$0$100
ADC Therapeutics
$1.60+5.96% today
-59.7% in 1 year
1-year low $0.961-year high $4.88
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What ADC Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $210 million in 2022 to $81.4 million in 2025, with -$143 million of profit last year.
SalesProfit
ADC Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ADC Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads ADC Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 210 | 70 | 71 | 81 | |
| 207 | 67 | 65 | 76 | |
| -123 | -165 | -130 | -107 | |
| -108 | -146 | -103 | -88 | |
| -157 | -240 | -158 | -143 | |
| -1.99 | -2.94 | -1.62 | -1.12 | |
| 98.4% | 96.4% | 91.6% | 92.9% | |
| -58.6% | -237.3% | -182.9% | -131.8% | |
| -74.9% | -345.1% | -222.8% | -175.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 491 | 355 | 322 | 323 |
| Cash | 326 | 279 | 251 | 261 |
| Total debt | 117 | 124 | 123 | 117 |
| Total liabilities | 411 | 503 | 525 | 509 |
| 79 | -148 | -203 | -186 | |
| 78 | 82 | 97 | 127 | |
| -44.2% | – | – | – | |
| -197.8% | 161.9% | 77.9% | 76.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -138 | -119 | -124 | -141 | |
| 1 | 3 | 1 | 0 | |
| -139 | -122 | -125 | -141 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 49 | 13 | 7 | 7 |
Valuation
- –
- –
- –
- -2.2×
- 2.8×
- –
- –
- -62.8%
- -63.4%
- 0.0%
Profitability
- 92.9%
- -131.8%
- -175.3%
- -110.9%
- -51.9%
- 199.4%
- 65.3%
- -47.0%
- -52.9%
- 119.9%
Growth
- −27.1%
- –
- −13.4%
- –
- +13.4%
Financial health
- -1.6×
- -1.95
- 144.5%
- -2.3×
- 4.09
- 4.02
- 0.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 958
Bottom 2%of 888
Bottom 4%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $7.50
- Range
- $5.00 – $10.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -0.21 | -0.19 | −10.5% |
| Mar 10, 2026 | -0.04 | -0.32 | +87.5% |
| Nov 10, 2025 | -0.30 | -0.40 | +25.0% |
| Aug 12, 2025 | -0.50 | -0.36 | −38.9% |
| May 14, 2025 | -0.36 | -0.38 | +5.3% |
| Mar 27, 2025 | -0.29 | -0.35 | +17.1% |
| Nov 7, 2024 | -0.42 | -0.36 | −16.7% |
| Aug 6, 2024 | -0.38 | -0.44 | +13.6% |
News
Cullinan Therapeutics reports Q3 resultsSeeking Alpha · Nov 10, 2026Enliven Therapeutics GAAP EPS of -$0.36Seeking Alpha · Nov 6, 2026Cognition Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Kymera Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 29, 2026LENZ Therapeutics GAAP EPS of -$0.99 misses by $0.04, revenue of $3.38M misses by $0.82MSeeking Alpha · Oct 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
49No pass
Benjamin Graham
47No pass
Philip Fisher
55No pass
Peter Lynch
4No pass
Joel Greenblatt
4No pass
Charlie Munger
54No pass
Terry Smith
54No pass
Questions about ADC Therapeutics
Is ADC Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ADC Therapeutics AI analysis
What does ADC Therapeutics do?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. It is in Biotechnology.
Does ADC Therapeutics pay a dividend?
No. ADC Therapeutics does not pay a dividend at the moment.
Is ADC Therapeutics stock halal?
No. ADC Therapeutics does not pass our halal screen: its debt is 52% of its market value, at or above the 33% limit. How we check
How has ADC Therapeutics stock done over the past year?
Down 59.7% over the past twelve months, to $1.60. It traded between $0.96 and $4.88 and is 67.2% below its high.
Who are ADC Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with ADC Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.